Steven M Freedman

US Patent:

6552081, Apr 22, 2003

Filed:

Nov 3, 2000

Appl. No.:

09/706404

Inventors:

Steven Freedman - Brighton MA
Juan G. Alvarez - Boston MA

Assignee:

Beth Israel Deaconess Medical Center, Inc. - Boston MA

International Classification:

A61K 3120

US Classification:

514560, 514558

Abstract:

A method of treating disorders in which DHA levels are affected is described. The method includes administering to a subject suffering from the disorder a therapeutically affective amount of DHA. This method is particularly useful in treating subjects suffering from a disorder characterized by a defect in the CF gene, e. g. , cystic fibrosis, or a chronic inflammatory disorder, e. g. , ulcerative colitis, Crohns disease, chronic pancreatitis, asthma, rheumatoid arthritis or chronic gastritis. A method of ameliorating affects of cystic fibrosis in a newborn and a method of increasing surfactant levels in a fetus are also described.

US Patent:

7981915, Jul 19, 2011

Filed:

Oct 31, 2005

Appl. No.:

11/262645

Inventors:

Steven D. Freedman - Chestnut Hill MA, US

Assignee:

Beth Israel Deaconess Medical Center - Boston MA

International Classification:

A61K 31/415
A61K 31/335
A61K 31/34
A61K 31/195
A61K 31/19
A61K 31/08

US Classification:

514396, 514458, 514474, 514561, 514562, 514570, 514722

Abstract:

This invention features methods for treating diseases associated with mutations in the CFTR gene by administering PPAR agonists, specifically PPARγ, PPARα, and PPARδ agonists, PPAR inducers, and/or antioxidants. Also disclosed are screening methods for identifying therapeutically useful candidate compounds.

US Patent:

20040127567, Jul 1, 2004

Filed:

Apr 8, 2003

Appl. No.:

10/410511

Inventors:

Steven Freedman - Brighton MA, US
Juan Alvarez - Boston MA, US

Assignee:

Beth Israel Deaconess Medical Center, Inc.

International Classification:

A61K031/202

US Classification:

514/560000

Abstract:

A method of treating disorders in which DHA levels are affected is described. The method includes administering to a subject suffering from the disorder a therapeutically affective amount of DHA. This method is particularly useful in treating subjects suffering from a disorder characterized by a defect in the CF gene, e.g., cystic fibrosis, or a chronic inflammatory disorder, e.g., ulcerative colitis, Crohn's disease, chronic pancreatitis, asthma, rheumatoid arthritis or chronic gastritis. A method of ameliorating affects of cystic fibrosis in a newborn and a method of increasing surfactant levels in a fetus are also described.

US Patent:

20100239559, Sep 23, 2010

Filed:

Oct 9, 2009

Appl. No.:

12/587579

Inventors:

Steven Freedman - Chestnut Hill MA, US
Deborah A. DaSilva - Sount Easton MA, US

Assignee:

Beth Israel Deaconess Medical Center, Inc. - Boston MA

International Classification:

A61K 38/46
A61K 38/47
A61K 38/48
C12N 9/20
C12N 9/26
C12N 9/48
A61P 1/14

US Classification:

424 9461, 424 946, 424 9463, 435198, 435201, 435212

Abstract:

The present invention is directed to novel food products, e.g., nutritional food products and infant formula, which contain one ore more enzymes selected from lipase, protease, and amylase that have been formulated/stabilized to have sustained stability in an aqueous medium. Such formulations are intended to provide a greater degree of compliance based on their ability to be incorporated into aqueous media while avoiding unstable breakdown of the enzyme and large overdosing due to expected breakdown when exposed to an aqueous environment, including saliva. Further described in the invention are additives packaged with instructions for combination with an aqueous medium, and instructions for the administration of the resulting mixture to a subject. In certain embodiments, enzyme insufficient patients, e.g., infants and elderly persons, would find particular benefit from the food products described herein.

US Patent:

61806714, Jan 30, 2001

Filed:

Feb 11, 1999

Appl. No.:

9/248471

Inventors:

Steven Freedman - Brighton MA
Juan G. Alvarez - Boston MA

Assignee:

Beth Israel Deaconess Medical Center, Inc. - Boston MA

International Classification:

A61K 3120

US Classification:

514560

Abstract:

A method of treating disorders in which DHA levels are affected is described. The method includes administering to a subject suffering from the disorder a therapeutically affective amount of DHA. This method is particularly useful in treating subjects suffering from a disorder characterized by a defect in the CF, gene, e. g. cystic fibrosis, or a chronic inflammatory disorder, e. g. , ulcerative colitis, Crohn's disease, chronic pancreatitis, asthma, rheumatoid arthritis or chronic gastritis. A method of ameliorating affects of cystic fibrosis in a newborn and a method of increasing surfactant levels in a fetus are also described.

US Patent:

56517696, Jul 29, 1997

Filed:

Oct 16, 1995

Appl. No.:

8/543612

Inventors:

Irving Waxman - Newton MA
Steven Freedman - Brighton MA

Assignee:

The Beth Israel Hospital Association - Boston MA

International Classification:

A61M 3100

US Classification:

604 54

Abstract:

A method for accurately and quickly positioning a double lumen gastroduodenal tube into predetermined locations utilizing an endoscopically placed guide wire to retrieve duodenal fluid uncontaminated by gastric fluid, with little or no discomfort to the patient, and minimal radiation exposure. Specifically, an endoscope is passed through a patent's esophagus and stomach into the duodenum such that its distal end is located at a predetermined location, such as the fourth portion of the duodenum. While the endoscope is held in place, a guide-wire is passed through its center instrument channel to position a distal end of the guide-wire adjacent to the distal end of the endoscope. The endoscope is then withdrawn from the patient, leaving the guide-wire. A double lumen gastroduodenal tube is then threaded over the guide-wire such that gastric ports are aligned with the stomach and duodenal ports are aligned with the fourth portion of the duodenum so that upon aspiration of the gastric ports, the gastric fluid is prevented from entering the duodenum and contaminating the duodenal fluid.